Axsome Therapeutics, Inc.
Current- Director 2026 to present
Executive record
Alpha ID: alpha:person:hunter-murdock-esq-axsmVersion: public-0As of: 2026-10-01
Connect capital, control, accountability, and evidence.
Mr. Murdock has served as General Counsel since June 2022, previously serving as EVP Legal and Compliance. He began his legal career at White & Case LLP, became a partner at Kirkland & Ellis LLP, and most recently served as VP and General Counsel of Aurobindo Pharma USA and Acrotech Biopharma.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAlpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
sec filing · Source published: Apr 24, 2026 · Retrieved: May 14, 2026
sec proxy · Source published: Apr 24, 2026 · Retrieved: Sep 2, 2026
sec filing · Source published: Date unavailable · Retrieved: May 3, 2026
public source · Source published: Date unavailable · Retrieved: Date unavailable
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01